ÌÇÐÄvlog

[Skip to Navigation]
Sign In

October 2024 - July 1959

Decade

Year

Issue

July 2021, Vol 78, No. 7, Pages 782-882

Viewpoint

Discontinuation of Disease-Modifying Therapy in Multiple Sclerosis: Should We Stay or Should We Go?

Abstract Full Text
JAMA Neurol. 2021;78(7):787-788. doi:10.1001/jamaneurol.2021.0764

This Viewpoint discusses the long-term effects of disease-modifying therapy in patients with multiple sclerosis and discusses the potential of discontinuing it in older patients.

Helping the Public Understand Adverse Events Associated With COVID-19 Vaccinations: Lessons Learned From Functional Neurological Disorder

Abstract Full Text
free access
JAMA Neurol. 2021;78(7):789-790. doi:10.1001/jamaneurol.2021.1042

This Viewpoint discusses potential associations between functional neurological disorder and COVID-19 vaccinations.

On the Brain

The Great Escape—A Physician Confronts Family Caregiving During the COVID-19 Pandemic

Abstract Full Text
free access
JAMA Neurol. 2021;78(7):791-792. doi:10.1001/jamaneurol.2021.1170

This essay discusses the struggles of family caregiving during the COVID-19 pandemic.

Editorial

Bad Air and Parkinson Disease—The Fog May Be Lifting

Abstract Full Text
JAMA Neurol. 2021;78(7):793-795. doi:10.1001/jamaneurol.2021.0863

Ischemic Events After Intracerebral Hemorrhage: A New Target for Secondary Prevention

Abstract Full Text
JAMA Neurol. 2021;78(7):795-797. doi:10.1001/jamaneurol.2021.0772

Discontinuing Antiseizure Medication in Neonates With Acute Symptomatic Seizures—Primum non nocere

Abstract Full Text
JAMA Neurol. 2021;78(7):797-799. doi:10.1001/jamaneurol.2021.1218
Original Investigation

Association of NO2 and Other Air Pollution Exposures With the Risk of Parkinson Disease

Abstract Full Text
free access has audio
JAMA Neurol. 2021;78(7):800-808. doi:10.1001/jamaneurol.2021.1335

This cohort study investigates the potential association between exposure to particulate matters (PM2.5 and PM10), nitrogen dioxide (NO2), ozone (O3), sulfur dioxide (SO2), and carbon monoxide (CO) and the risk of incident Parkinson disease.

Association Between Intracerebral Hemorrhage and Subsequent Arterial Ischemic Events in Participants From 4 Population-Based Cohort Studies

Abstract Full Text
free access
JAMA Neurol. 2021;78(7):809-816. doi:10.1001/jamaneurol.2021.0925

This analysis of pooled cohort data from 4 popluation-based cohort studies evaluates whether intracerebral hemorrhage was associated with an increased risk of incident ischemic stroke and myocardial infarction.

Safety of Early Discontinuation of Antiseizure Medication After Acute Symptomatic Neonatal Seizures

Abstract Full Text
open access
JAMA Neurol. 2021;78(7):817-825. doi:10.1001/jamaneurol.2021.1437

This comparative effectiveness study assesses whether discontinuation of antiseizure medication prior to discharge from the hospital after resolution of acute symptomatic neonatal seizures is associated with impaired functional neurodevelopment or the risk of epilepsy at 24 months.

Assessment of Recurrent Stroke Risk in Patients With a Carotid Web

Abstract Full Text
free access
JAMA Neurol. 2021;78(7):826-833. doi:10.1001/jamaneurol.2021.1101

This cohort study assesses the recurrent stroke risk in a population of patients with a large vessel occlusion stroke of the anterior circulation and ipsilateral carotid web.

Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy

Abstract Full Text
open access
JAMA Neurol. 2021;78(7):834-841. doi:10.1001/jamaneurol.2021.1272

This ongoing follow-up study of the START phase 1 clinical trial assesses the long-term safety and efficacy of onasemnogene abeparvovec in infants with spinal muscular atrophy type 1.

Association of a Marker of N-Acetylglucosamine With Progressive Multiple Sclerosis and Neurodegeneration

Abstract Full Text
open access
JAMA Neurol. 2021;78(7):842-852. doi:10.1001/jamaneurol.2021.1116

This cross-sectional study investigates a marker of endogenous serum N-acetylglucosamine levels in patients with multiple sclerosis (MS).

Clinicopathologic Features of Oculopharyngodistal Myopathy With LRP12 CGG Repeat Expansions Compared With Other Oculopharyngodistal Myopathy Subtypes

Abstract Full Text
free access
JAMA Neurol. 2021;78(7):853-863. doi:10.1001/jamaneurol.2021.1509

This case series identifies and characterizes the clinicopathologic features of patients with oculopharyngodistal myopathy with CGG repeat expansion in LRP12.

Review

Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review

Abstract Full Text
JAMA Neurol. 2021;78(7):864-873. doi:10.1001/jamaneurol.2021.0249

This systematic review evaluates the presentation of immune checkpoint inhibitor–induced encephalitis to identify features helpful in assessing outcomes.

Images in Neurology

Flapping Scalp Sign as a Rare and Interesting Presentation in Delayed Postoperative Tension Pneumocephalus

Abstract Full Text
has multimedia
JAMA Neurol. 2021;78(7):874-875. doi:10.1001/jamaneurol.2021.1149

This case report describes abnormal movement of the scalp after surgery to repair a compound, depressed, comminuted right frontal bone fracture involving the frontal sinus.

Primary Central Nervous System Lymphoma With Symmetrical Pyramidal Tract Hyperintensity

Abstract Full Text
JAMA Neurol. 2021;78(7):876-877. doi:10.1001/jamaneurol.2021.1165

This case report describes a woman with a rare bilateral case of primary central nervous system lymphoma.

JAMA Neurology Clinical Challenge

Sequential Bilateral Vision Loss in a Woman With Scalp Tenderness and Jaw Claudication

Abstract Full Text
JAMA Neurol. 2021;78(7):878-879. doi:10.1001/jamaneurol.2021.0757

A 67-year-old woman with fibromyalgia presents with sequential bilateral vision loss; scalp tenderness; jaw claudication; neck, shoulder, and back pain; and recent weight loss. What is your diagnosis?

Research Letter

SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort

Abstract Full Text
free access
JAMA Neurol. 2021;78(7):880-882. doi:10.1001/jamaneurol.2021.1364

This cohort study assesses a group of patients with multiple sclerosis in Amsterdam, the Netherlands, for SARS-CoV-2 antibodies to quantify asymptomatic infections and immunological response to COVID-19.

Correction

Errors in Figure 2

Abstract Full Text
free access
JAMA Neurol. 2021;78(7):882. doi:10.1001/jamaneurol.2021.1617

CC-BY Open Access Added

Abstract Full Text
free access
JAMA Neurol. 2021;78(7):882. doi:10.1001/jamaneurol.2021.2227
JAMA Neurology Masthead

JAMA Neurology

Abstract Full Text
free access
JAMA Neurol. 2021;78(7):782. doi:10.1001/jamaneurol.2020.3673
×